PACAP and type I PACAP receptors in human prostate cancer tissue

Annals of the New York Academy of Sciences

Volumn 1070, Issue , 2006, Pages 440-449

  Moretti, Costanzo ^a   Mammi, Caterina ^b   Frajese, Giovanni Vanni ^a   Mariani, Stefania ^c   Gnessi, Lucio ^c   Arizzi, Mario ^c   Wannenes, Francesca ^b   Frajese, Gaetano ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

BPH; PAC1 R; PACAP; PACAP receptor variants; Prostate; Prostate cancer; SV1; SV2; SV3

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; PEROXIDASE;

ADULT; AGED; CANCER SURGERY; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; EPITHELIUM CELL; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; STROMA CELL; TUMOR BIOPSY;

EID: 33746422499     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1317.059     Document Type: Conference Paper

References (38)

1. MIYATA, A. et al. 1989. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 164: 567-574.
2. HOSOYA, M. et al. 1992. Structure of the human pituitary adenylate cyclase activating polypeptide (PACAP) gene. Biochem. Biophys. Acta 1129: 199-206.
3. CANNY, B.J., S.R. RAWLINGS & D.A. LEONG. 1992. Pituitary adenylate cyclase activating polypeptide specifically increases cytosolic calcium ion concentration in rat gonadotropes and somatotropes. Endocrinology 130: 211-215.
4. DEUTSCH, P.J. & Y. SUN. 1992. The 38-amino acid pituitary adenylate cyclase activating polypeptide stimulates dual signalling cascades in PC12 cells and promotes neurite outgrowth. J. Biol. Chem. 267: 5108-5113.
5. TATSUNO, I., T. YADA, S. VIGH, et al. 1992. Pituitary adenylate cyclase activating polypeptide and vasoactive intestinal peptide increase cytosolic free calcium concentration in cultured rat hippocampal neurons. Endocrinology 31: 73-81.
6. WATANABE, T. et al. 1992. Pituitary adenylate cyclase activating polypeptide provokes cultured rat chromaffin cells to secrete adrenaline. Biochem. Biophys. Res. Commun. 182: 403-411.
7. ARIMURA, A. & S. SHIODA. 1995. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and endocrine interaction. Front. Neuroendocrinol. 16: 53-88.
8. UDDMAN, R., A. LUTS, A. ARIMURA & F. SUNDLER. 1991. Pituitary adenylate cyclase activating polypeptide (PACAP), a new vasoactive intestinal peptide (VIP)-like peptide in the respiratory tract. Cell Tissue Res. 265: 197-201.
9. GARCÌA-FERNÀNDEZ, M.O. et al. 2002. Expression and distribution of pituitary adenylate cyclase-activating peptide in human prostate and prostate cancer tissues. Regul. Pept. 110: 9-15.
10. HARMAR, A.J. et al. 1998. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev. 50: 265-270.
11. PISEGNA, J.R. & S.A. WANK. 1996. Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. J. Biol. Chem. 271: 17267-17274.
12. HASHIMOTO, H. et al. 1996. Distribution of the mRNA for a pituitary adenylate cyclase activating polypeptide receptor in the rat brain: an in situ hybridization study. J. Comp. Neurol. 371: 567-577.
13. SUDA, K., D.M. SMITH, M.A. GHATEI, et al. 1991. Investigation and characterization of receptors for pituitary adenylate cyclase-activating polypeptide in human brain by radioligand binding and chemical cross-linking. J. Clin. Endocrinol. Metab. 72: 958-964.
14. LUTZ-BUCHER, B., D. MONNIER & B. KOCH. 1996. Evidence for the presence of receptors for pituitary adenylate cyclase-activating polypeptide in the neurohypophysis that are positively coupled to cyclic AMP formation and neurohypophyseal hormone secretion. Neuroendocrinology 64: 153-161.
15. HART, G.R., H. GOWING & J.M. BURRIN. 1992. Effects of a novel hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide, on pituitary release in rats. J. Endocrinol. 134: 33-41.
16. ROMANELLI, F., S. FILLO, A. ISIDORI & D. CONTE. 1997. Pituitary adenylate cyclase-activating polypeptide regulates rat Leydig cell function in vitro. Neuropeptides 31: 311-317.
17. WATANABE, T. et al. 1992. Pituitary adenylate cyclase-activating polypeptide provokes cultured rat chromaffin cells to secrete adrenaline. Biochem. Biophys. Res. Commun. 182: 403-411.
18. SOLANO, R.M. et al. 1996. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase activating peptide receptors in human benign hyperplastic prostate. Endocrinology 137: 2815-2822.
19. 1) receptor in human benign hyperplastic prostate. Cell. Signal. 11: 813-819.
20. REUBI, J.C. 2000. In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann. N. Y. Acad. Sci. 921: 1-25.
21. JUARRANZ, M.G., O. BOLAÑOS, I. GUTIERREZ-CAÑAS, et al. 2001. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors. Cell. Signal. 13: 887-894.
22. PISEGNA, J.R. & S.A. WANK. 1996. Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. J. Biol. Chem. 271: 17267-17274.
23. VAUDRY, D., B.J. GONZALEZ, M. BASILLE, et al. 2000. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol. Rev. 52: 269-324.
24. FARINI, D., A. PUGLIANIELLO, C. MAMMI, et al. 2003. Dual effect of pituitary adenylate cyclase activating polypeptide on prostate tumor LNCaP cells: short-and long-term exposure affect proliferation and neuroendocrine differentiation. Endocrinology 144: 1631-1643.
25. MCNEAL, J.E., R.J. COHEN & J.D. BROOKS. 2001. Role of cytologic criteria in the histologic diagnosis of Gleason grade 1 prostatic adenocarcinoma. Hum. Pathol. 32: 441-446.
26. CHOMCZYNSKI, P. & N. SACCHI. 1992. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159.
27. HOSOYA, M. et al. 1992. Structure of the human pituitary adenylate cyclase activating polypeptide (PACAP) gene. Biochem. Biophys. Acta 1129: 199-206.
28. CAMPS, J.L. et al. 1990. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc. Natl. Acad. Sci. USA 87: 75-79.
29. CHUNG, L.W. & R. DAVIES. 1996. Prostate epithelial differentiation is dictated by its surrounding stroma. Mol. Biol. Rep. 23: 13-19.
30. THALMANN, G.N. et al. 1994. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 54: 2577-2581. Erratum in: Cancer Res. 54: 3953.
31. TLSTY, T.D. 1998. Cell-adhesion-dependent influences on genomic instability and carcinogenesis. Curr. Opin. Cell. Biol. 10: 647-653.
32. METTE, A.P. & E.A. OSTRANDER 2001. Prostate cancer: simplicity to complexity. Nature Genetics 27: 134-135.
33. DEBES, J.D. & D.J. TINDALL. 2004. Mechanism of androgen-refractory prostate cancer. N. Engl. J. Med. 351: 1488-1490.
34. YU, D.S., D.S. HSIEH, H.I. CHEN & S.Y. CHANG. 2001. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications. J. Urol. 166: 871-875.
35. DI SANT'AGNESE, P.A. 1992. Neuroendocrine differentiation in human prostatic carcinoma. Hum. Pathos. 23: 287-296.
36. BONKHOFF, H., U. STEIN, K. ROMBERG. 1995. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum. Pathol. 26: 167-170.
37. ABRAHAMSSON, P.T. 1999. Neuroendocrine cells in tumor growth of the prostate. Endocrine Relat. Cancer 6: 503-519.
38. LEYTON, J., T. COELHO, D.H. COY, et al. 1998. PACAP(6-38) inhibits the growth of prostate cancer cells. Cancer Lett. 125: 131-139.